Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329194 · ClinicalTrials.gov registry record · Phase 4
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 287
- Enrollment target
NCT05329194 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 287 participants.
The verdict
NCT05329194, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 287 participants
- Enrollment target
Study Summary
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Interventions
- DRUG Tezepelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2025-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05329194
The ClinicalTrials.gov registry entry for NCT05329194 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tezepelumab is the first listed.
NCT05329194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05329194 about?
NCT05329194 is a clinical study titled "Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States". To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
What is the current status of trial NCT05329194?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 287 participants. The study started on 2022-04-29. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT05329194?
The interventions under investigation include: Tezepelumab (DRUG).
Who is sponsoring clinical trial NCT05329194?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.